Correlation of serum adenosine deaminase activity with disease activity in patients with primary Sjögren's syndrome.
暂无分享,去创建一个
L. Geng | Zhiye Xu | K. Dong | Hongling Ye | Ying Wang | Sen Wang | Hairong Zhang
[1] Lijun Wu,et al. Hyperglobulinemia predicts increased risk of mortality in primary Sjögren's syndrome: based on a Chinese multicentre registry. , 2023, Modern rheumatology.
[2] Teng Zhang,et al. The immunomodulatory function of adenosine in sepsis , 2022, Frontiers in Immunology.
[3] E. Oleinik,et al. Adenosine-Metabolizing Enzymes, Adenosine Kinase and Adenosine Deaminase, in Cancer , 2022, Biomolecules.
[4] Han Shen,et al. Increased serum adenosine deaminase activity in patients with adult-onset Still's disease , 2022, BMC immunology.
[5] K. Baumgart,et al. Candidate autoantibodies for primary Sjögren's syndrome: where are they now? , 2021, Clinical and experimental rheumatology.
[6] X. Mariette,et al. Current and future therapies for primary Sjögren syndrome , 2021, Nature Reviews Rheumatology.
[7] S. Negrini,et al. Sjögren’s syndrome: a systemic autoimmune disease , 2021, Clinical and Experimental Medicine.
[8] G. Norata,et al. HDL in Immune-Inflammatory Responses: Implications beyond Cardiovascular Diseases , 2021, Cells.
[9] K. Dong,et al. The roles of adenosine deaminase in autoimmune diseases. , 2020, Autoimmunity reviews.
[10] E. Latz,et al. High-Density Lipoproteins Decrease Proinflammatory Activity and Modulate the Innate Immune Response. , 2019, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[11] I. Meyts,et al. Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment , 2018, Journal of Clinical Immunology.
[12] M. Garcia-Gil,et al. The Inside Story of Adenosine , 2018, International journal of molecular sciences.
[13] M. Kakei,et al. High-density lipoprotein and apolipoprotein A-I inhibit palmitate-induced translocation of toll-like receptor 4 into lipid rafts and inflammatory cytokines in 3T3-L1 adipocytes. , 2017, Biochemical and biophysical research communications.
[14] A. Zavialov,et al. Human adenosine deaminases ADA1 and ADA2 bind to different subsets of immune cells , 2017, Cellular and Molecular Life Sciences.
[15] K. Dong,et al. The role of adenosinergic pathway in human autoimmune diseases , 2016, Immunologic research.
[16] J. Parks,et al. New roles of HDL in inflammation and hematopoiesis. , 2012, Annual review of nutrition.
[17] F. Da Settimo,et al. Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders. , 2012, Current drug targets.
[18] R. Krenke,et al. [Role of biomarkers in making the diagnosis of tuberculous pleurisy]. , 2011, Pneumonologia i alergologia polska.
[19] C. Gabay,et al. Serum lipoproteins attenuate macrophage activation and Toll-Like Receptor stimulation by bacterial lipoproteins , 2010, BMC Immunology.
[20] R. Krenke,et al. Use of pleural fluid levels of adenosine deaminase and interferon gamma in the diagnosis of tuberculous pleuritis , 2010, Current opinion in pulmonary medicine.
[21] T. Palmer,et al. Suppression of inflammatory and immune responses by the A2A adenosine receptor: an introduction , 2008, British journal of pharmacology.
[22] S. Bombardieri,et al. Sjögren's Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients. , 2007, Arthritis and rheumatism.
[23] G. Cristalli,et al. Adenosine deaminase: Functional implications and different classes of inhibitors , 2001, Medicinal research reviews.
[24] F. Marumo,et al. Adenosine deaminase isoenzymes in liver disease. , 1993, The American journal of gastroenterology.
[25] M. Weyden,et al. Human adenosine deaminase. Distribution and properties. , 1976, The Journal of biological chemistry.
[26] Gholamreza Sharifzadeh,et al. Hematologic parameters and disease activity in patients with primary Sjögren's syndrome , 2022, The Egyptian Rheumatologist.